1. |
Moley JF, Fialkowski EA.Evidence-based approach to the management of sporadic medullary thyroid carcinoma[J].World J Surg, 2007, 31(5):946-956.
|
2. |
Ferreira CV, Siqueira DR, Ceolin L, et al.Advanced medullary thyroid cancer:pathophysiology and management[J].Cancer Manag Res, 2013, 5:57-66.
|
3. |
刘跃武, 王梦一.甲状腺髓样癌诊治的若干问题[J].临床外科杂志, 2012, 20(7):455-456.
|
4. |
樊友本, 郭伯敏.以CEA增高为主要表现的甲状腺髓样癌一例[J].中华普通外科杂志, 2009, 24(6):513.
|
5. |
Sugawara M, Ly T, Hershman JM.Medullary thyroid cancer-current treatment strategy, novel therapies and perspectives for the future[J].Horm Cancer, 2012, 3(5/6):218-226.
|
6. |
Cummings AL, Goldfarb M.Thyroid carcinoma metastases to axillary lymph nodes:report of two rare cases of papillary and medullary thyroid carcinoma and literature review[J].Endocr Pract, 2014, 20(3):e34-e37.
|
7. |
Braudao LG, Cavalheiro BG, Junqueira CR.Prognostic influence of clinical and pathological factors in medullary thyroid carcinoma:a study of 53 cases[J].Clinics (Sao Paulo), 2009, 64(9):849-856.
|
8. |
唐平章.美国国立综合癌症网(NCCN)2010年版甲状腺肿瘤治疗指南解读[J].中国实用外科杂志, 2010, 30(10):856-858.
|
9. |
Lupone G, Antonino A, Rosato A, et al.Surgical strategy for the treatment of sporadic medullary thyroid carcinoma:our experience[J].G Chir, 2012, 33(11/12):395-399.
|
10. |
Stamatakos M, Paraskeva P, Stefanaki C, et al.Medullary thyroid carcinoma:The third most common thyroid cancer reviewed[J].Oncol Lett, 2011, 2(1):49-53.
|
11. |
Pinto AE, Silva GL, Henrique R, et al.Familial vs sporadic papillary thyroid carcinoma:a matched-case comparative study showing similar clinical/prognostic behaviour[J].Eur J Endocrinol, 2014, 170(2):321-327.
|
12. |
Alevizaki M, Saltiki K, Rentziou GA, et al.Medullary thyroid carcinoma:the influence of policy changing in clinical characteristics and disease progression[J].Eur J Endocrinol, 2012, 167(6):799-808.
|
13. |
Milan SA, Sosa JA, Roman SA.Current management of medullary thyroid cancer[J].Minerva Chir, 2010, 65(1):27-37.
|
14. |
Moo-Young TA, Traugott AL, Moley JF.Sporadic and familial medullary thyroid carcinoma:state of the art[J].Surg Clin North Am, 2009, 89(5):1193-1204.
|
15. |
Stamatakos M, Paraskeva P, Katsaronis P, et al.Surgical approach to the management of medullary thyroid cancer:when is lymph node dissection needed?[J].Oncology, 2013, 84(6):350-355.
|
16. |
Welch K, McHenry CR.Selective lateral compartment neck dissection for thyroid cancer[J].J Surg Res, 2013, 184(1):193-199.
|
17. |
Ma SH, Liu QJ, Zhang YC, et al.Alternative surgical strategies in patients with sporadic medullary thyroid carcinoma:Long-term follow-up[J].Oncol Lett, 2011, 2(5):975-980.
|
18. |
张再兴, 李正江, 唐平章, 等.甲状腺髓样癌的外科治疗及预后分析[J].中华耳鼻咽喉头颈外科杂志, 2011, 46(3):209-213.
|
19. |
Dralle H, Musholt TJ, Schabram JA, et al.German Association of Endocrine Surgeons Practice Guideline for the surgical management of malignant thyroid tumors[J].Langenbecks Arch Surg, 2013, 398(3):347-375.
|
20. |
De Crea C, Raffaelli M, Milano V, et al.Is intraoperative calcitonin monitoring useful to modulate the extension of neck dissection in patients with medullary thyroid carcinoma?[J].World J Surg, 2014, 38(3):568-575.
|
21. |
Machens A, Dralle H.Biomarker-based risk stratification for previously untreated medullary thyroid cancer[J].J Clin Endocrinol Metab, 2010, 95(6):2655-2663.
|
22. |
Essig GF Jr, Porter K, Schneider D, et al.Fine needle aspiration and medullary thyroid carcinoma:the risk of inadequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone[J].Endocr Pract, 2013, 19(6):920-927.
|
23. |
Pusztaszeri MP, Bongiovanni M, Faquin WC.Update on the cytologic and molecular features of medullary thyroid carcinoma[J].Adv Anat Pathol, 2014, 21(1):26-35.
|
24. |
Machens A, Dralle H.Benefit-risk balance of reoperation for persistent medullary thyroid cancer[J].Ann Surg, 2013, 257(4):751-757.
|
25. |
Martínez-Rodríguez I, Banzo I, Carril JM.Metabolic response demonstrated by 18F-FDG-PET/CT in metastatic medullary thyroid carcinoma under sorafenib therapy[J].Endocrine, 2013, 44(1):264-265.
|
26. |
Slavikova K, Montravers F, Treglia G, et al.What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?[J].Curr Radiopharm, 2013, 6(2):96-105.
|